| Literature DB >> 30545920 |
Livingstone Fultang1, Laura D Gamble2, Luciana Gneo1, Andrea M Berry3, Sharon A Egan4, Fenna De Bie1, Orli Yogev5, Georgina L Eden2, Sarah Booth1, Samantha Brownhill3, Ashley Vardon1, Carmel M McConville6, Paul N Cheng7, Murray D Norris2, Heather C Etchevers8, Jayne Murray2, David S Ziegler2, Louis Chesler5, Ronny Schmidt9, Susan A Burchill3, Michelle Haber2, Carmela De Santo1, Francis Mussai10.
Abstract
Neuroblastoma is the most common childhood solid tumor, yet the prognosis for high-risk disease remains poor. We demonstrate here that arginase 2 (ARG2) drives neuroblastoma cell proliferation via regulation of arginine metabolism. Targeting arginine metabolism, either by blocking cationic amino acid transporter 1 (CAT-1)-dependent arginine uptake in vitro or therapeutic depletion of arginine by pegylated recombinant arginase BCT-100, significantly delayed tumor development and prolonged murine survival. Tumor cells polarized infiltrating monocytes to an M1-macrophage phenotype, which released IL1β and TNFα in a RAC-alpha serine/threonine-protein kinase (AKT)-dependent manner. IL1β and TNFα established a feedback loop to upregulate ARG2 expression via p38 and extracellular regulated kinases 1/2 (ERK1/2) signaling in neuroblastoma and neural crest-derived cells. Proteomic analysis revealed that enrichment of IL1β and TNFα in stage IV human tumor microenvironments was associated with a worse prognosis. These data thus describe an immune-metabolic regulatory loop between tumor cells and infiltrating myeloid cells regulating ARG2, which can be clinically exploited. SIGNIFICANCE: These findings illustrate that cross-talk between myeloid cells and tumor cells creates a metabolic regulatory loop that promotes neuroblastoma progression. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30545920 PMCID: PMC6420118 DOI: 10.1158/0008-5472.CAN-18-2139
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701